As Shkre­li at­tor­ney Greebel heads to his own prison cell, the bad boy of biotech is still skew­er­ing en­e­mies in new blog

Late last week Evan Greebel was sen­tenced to 18 months in prison for his role in Mar­tin Shkre­li’s scheme to de­fraud in­vestors. And he’s be­ing forced to pay more than $10 mil­lion in resti­tu­tion to Retrophin, a biotech Shkre­li had found­ed which fed­er­al pros­e­cu­tors would go on to al­lege was turned in­to Shkre­li’s own per­son­al pig­gy­bank as he sought to pump up the stock and re­pay those same in­vestors he was con­vict­ed of ly­ing to.

“I will re­gret every day of my life the day I met Mar­tin Shkre­li,” Greebel told the court, ac­cord­ing to the Wall Street Jour­nal. And he’ll have lots of time to think on that con­nec­tion.

Shkre­li, now serv­ing a 7-year sen­tence for fraud at the low-se­cu­ri­ty fed­er­al cor­rec­tion­al in­sti­tute at Fort Dix, will have to spend much more time be­hind bars. But he’s al­ready found an out­let for en­ter­tain­ing a much larg­er au­di­ence than he can find in prison.

Shkre­li’s been post­ing a reg­u­lar blog piece at mar­tin­shkre­li.com, and it’s giv­en the “most hat­ed man in Amer­i­ca” with the no­to­ri­ous smirk a fo­rum while of­fer­ing peo­ple a chance to take their own shots back — or of­fer up some cheers from the dis­tant side­lines of the pen­i­ten­tiary sys­tem.

This is a much tamer Shkre­li than the bad boy of biotech who was re­peat­ed­ly boot­ed from Twit­ter for stalk­ing a fe­male jour­nal­ist with creepy mes­sages, or who once got a kick out of send­ing me an ob­scen­i­ty-laced rap song and added email warn­ings about my “loss-of-func­tion mu­ta­tion – do not re­pro­duce” and oth­er per­ceived short­com­ings.

In or­der to avoid ril­ing prison au­thor­i­ties, who con­trol these things, Shkre­li is of­fer­ing up a steady stream of toned down seg­ments rang­ing from in­vest­ment ad­vice, both long and short, to his list of fa­vorite busi­ness books, the oc­ca­sion­al jibe at Hillary Clin­ton — “un­trust­wor­thy par­a­site” — and in­struc­tions for send­ing him mail.

He still en­joys tar­get­ing peo­ple, aside from Clin­ton, but the lan­guage is sig­nif­i­cant­ly less provoca­tive. One ex­am­ple:

Sarah Jeong join­ing the New York Times is a dis­grace.

And there’s lots of time to read at Fort Dix, with no short­age of read­ing ma­te­ri­als.

I’ve re­ceived around 500 books by mail since I en­tered the prison sys­tem. There is a Twi­light Zone episode, “Time Enough At Last” (I think that’s what it is called!), that sum­ma­rizes my feel­ings on hav­ing a lot of time to read. It’s a joy, but I don’t ex­act­ly have the shelf space. I prob­a­bly have around 50 books here at Fort Dix.

Shkre­li has about 6 more years of blog posts com­ing, if he serves the full time. That should be about 300 or so more blog posts. It’s un­like­ly he’ll tire of it.

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind.1,2 Not every person has access to innovative therapies designed specifically to treat his or her disease. Many currently available immuno-oncology-based approaches and chemotherapies have brought long-term benefits to some patients — but many patients still need other therapeutic options.3

Mark Genovese (Stanford via Twitter)

Gilead woos fil­go­tinib clin­i­cal in­ves­ti­ga­tor from Stan­ford to lead the charge on NASH, in­flam­ma­to­ry dis­eases

With an FDA OK for the use of filgotinib in rheumatoid arthritis expected to drop any day now, Gilead has recruited a new leader from academia to lead its foray into inflammatory diseases.

Mark Genovese — a longtime Stanford professor and most recently the clinical chief in the division of immunology and rheumatology — was the principal investigator in FINCH 2, one of three studies that supported Gilead’s NDA filing. In his new role as SVP, inflammation, he will oversee the clinical development of the entire portfolio.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

So let’s say you’re running a cutting-edge, clinical-stage biotech, probably public, but not necessarily so, which could see some big advantages teaming up with some marquee researchers, picking up say $50 million to $75 million dollars in a non-threatening minority equity investment that could take you to the next level.

Doug Giordano might have some thoughts on how that could work out.

The SVP of business development at the pharma giant has helped forge a new fund called the Pfizer Breakthrough Growth Initiative. And he has $500 million of Pfizer’s money to put behind 7 to 10 — or so — biotech stocks that fit that general description.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.

Stephen Isaacs, Aduro president and CEO (Aduro)

Once a high fly­er, a stag­ger­ing Aduro is auc­tion­ing off most of the pipeline as CEO Stephen Isaacs hands off the shell to new own­ers

After a drumbeat of failure, setbacks and reorganizations over the last few years, Aduro CEO Stephen Isaacs is handing over his largely gutted-out shell of a public company to another biotech company and putting up some questionable assets in a going-out-of-business sale.

Isaacs —who forged a string of high-profile Big Pharma deals along the way — has wrapped a 13-year run at the biotech with one program for kidney disease going to the new owners at Chinook Therapeutics. A host of once-heralded assets like their STING agonist program partnered with Novartis (which dumped their work on ADU-S100 after looking over weak clinical results), the Lilly-allied cGAS-STING inhibitor program and the anti-CD27 program out-licensed to Merck will all be posted for auction under a strategic review process.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis chips in $10M for IPO-bound part­ner Pli­ant; Tenax shares soar on heart drug da­ta

Novartis is coming in with $10 million to help support the looming IPO of a partner. Pliant Therapeutics posted a new filing with the SEC showing that Novartis is buying the shares at $15, the mid-point of the range. It’s adding several million shares to the offering, bringing the total to around $135 million. Biotech companies have been enjoying quite a run on virtual Wall Street, with investors boosting new offerings to some big hauls.

Gilead re­leas­es an­oth­er round of murky remde­sivir re­sults

A month after the NIH declared the first trial on remdesivir in Covid-19 a success, Gilead is out with new results on their antiviral. But although the study met one of its primary endpoints, the data are likely to only add to a growing debate over how effective the drug actually is.

In a Phase III trial, patients given a 5-day dose of remdesivir were 65% more likely to show “clinical improvement” compared to an arm given standard-of-care. The trial, though, gave little indication for whether the drug had an impact on key endpoints such as survival or time-to-recovery. And in a surprising twist, a 10-day dosing arm of remdesivir didn’t lead to a statistically significant improvement over standard of care.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.

Fangliang Zhang (Imaginechina via AP Images)

The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise $350M-plus on Nas­daq

Almost exactly three years after Shanghai-based Legend came out of nowhere to steal the show at ASCO with jaw-dropping data on their BCMA-targeted CAR-T for multiple myeloma, the little player with Big Pharma connections is taking a giant step toward making it big on Wall Street. And this time they want to seal the deal on a global rep after staking out a unicorn valuation in what’s turned out to be a bull market for biotech IPOs — in the middle of a pandemic.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bris­tol My­ers Squib­b's just-launched MS drug Zeposia makes the cut in key ul­cer­a­tive col­i­tis tri­al

In March, Zeposia became the third oral S1P modulator to secure US approval for multiple sclerosis. Now, the drug has succeeded in a key ulcerative colitis study.

The immunomodulator, akin to others in its class, controls lymphocyte trafficking by limiting the white blood cells to the lymphatic system, in the lymph nodes, and thwarting their ability to jam up lymph nodes — precluding their ability to penetrate the bloodstream and the central nervous system.

Hill­house re­casts spot­light on Chi­na's biotech scene with $160M round for Shang­hai-based an­ti­body mak­er

Almost two years after first buying into Genor Biopharma’s pipeline of cancer and autoimmune therapies, Hillhouse Capital has led a $160 million cash injection to push the late-stage assets over the finish line while continuing to fund both internal R&D and dealmaking.

The Series B has landed right around the time Genor would have listed on the Hong Kong stock exchange, according to plans reported by Bloomberg late last year. Insiders had said that the company was looking to raise about $200 million.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.